Capricor Therapeutics (CAPR) Stock
Small biotech developing cell therapies for rare heart conditions. Here's the price, business snapshot, and what's worth knowing about Capricor Therapeutics in October 2026.
Capricor Therapeutics Inc (CAPR) is a clinical‑stage biotechnology company focused on developing cell- and exosome-based therapies for cardiac and neuromuscular conditions. It pursues treatments aimed at heart repair and rare diseases, with a small market capitalisation of about $291.22 million, which typically points to relatively low liquidity and higher share-price volatility. Key investment considerations include binary clinical outcomes, lengthy regulatory and development timelines, manufacturing complexity and the usual biotech risks such as trial setbacks and funding needs. For investors, Capricor may offer upside if trials succeed, but losses are possible and time horizons can be long. This summary is educational and not personal financial advice; investors should review the company’s regulatory filings, trial data and consult a qualified adviser to assess suitability for their portfolios.
Capricor Therapeutics (CAPR) Stock Forecast
Analyst price target, next 12 months
$24.58
+314.6% vs today's $5.93
Price range over the last 12 months
Close to its 12-month low
Analysts covering Capricor Therapeutics have a consensus 12-month target of $24.58, above the current price of $5.93.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 24 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Capricor's stock with a target price of $24.58, indicating strong growth potential.
Financial Health
Capricor Therapeutics is showing promising financial stability and cash generation abilities.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage focus
Progress hinges on trial readouts and regulatory milestones, which can create sharp share-price moves; outcomes are uncertain and timelines can be long.
Rare disease potential
Targeting cardiac and neuromuscular conditions can offer significant unmet-need opportunities, though commercial success depends on safety, efficacy and reimbursement paths.
High-risk profile
Small market cap and development-stage status mean higher volatility and funding sensitivity — suitable mainly for investors who tolerate elevated risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
